These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37934115)

  • 1. CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.
    Prahallad A; Weiss A; Voshol H; Kerr G; Sprouffske K; Yuan T; Ruddy D; Meistertzheim M; Kazic-Legueux M; Kottarathil T; Piquet M; Cao Y; Martinuzzi-Duboc L; Buhles A; Adler F; Mannino S; Tordella L; Sansregret L; Maira SM; Graus Porta D; Fedele C; Brachmann SM
    Cancer Res; 2023 Dec; 83(24):4130-4141. PubMed ID: 37934115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
    Weiss A; Lorthiois E; Barys L; Beyer KS; Bomio-Confaglia C; Burks H; Chen X; Cui X; de Kanter R; Dharmarajan L; Fedele C; Gerspacher M; Guthy DA; Head V; Jaeger A; Núñez EJ; Kearns JD; Leblanc C; Maira SM; Murphy J; Oakman H; Ostermann N; Ottl J; Rigollier P; Roman D; Schnell C; Sedrani R; Shimizu T; Stringer R; Vaupel A; Voshol H; Wessels P; Widmer T; Wilcken R; Xu K; Zecri F; Farago AF; Cotesta S; Brachmann SM
    Cancer Discov; 2022 Jun; 12(6):1500-1517. PubMed ID: 35404998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling.
    Fedele C; Li S; Teng KW; Foster CJR; Peng D; Ran H; Mita P; Geer MJ; Hattori T; Koide A; Wang Y; Tang KH; Leinwand J; Wang W; Diskin B; Deng J; Chen T; Dolgalev I; Ozerdem U; Miller G; Koide S; Wong KK; Neel BG
    J Exp Med; 2021 Jan; 218(1):. PubMed ID: 33045063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
    Liu C; Lu H; Wang H; Loo A; Zhang X; Yang G; Kowal C; Delach S; Wang Y; Goldoni S; Hastings WD; Wong K; Gao H; Meyer MJ; Moody SE; LaMarche MJ; Engelman JA; Williams JA; Hammerman PS; Abrams TJ; Mohseni M; Caponigro G; Hao HX
    Clin Cancer Res; 2021 Jan; 27(1):342-354. PubMed ID: 33046519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
    Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H
    Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein Tyrosine Phosphatase Non-Receptor 11 (
    Richards CE; Elamin YY; Carr A; Gately K; Rafee S; Cremona M; Hanrahan E; Smyth R; Ryan D; Morgan RK; Kennedy S; Hudson L; Fay J; O'Byrne K; Hennessy BT; Toomey S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445722
    [No Abstract]   [Full Text] [Related]  

  • 7. Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.
    Khan HY; Nagasaka M; Aboukameel A; Alkhalili O; Uddin MH; Bannoura SF; Mzannar Y; Azar I; Beal EW; Tobon ME; Kim SH; Beydoun R; Baloglu E; Senapedis W; El-Rayes BF; Philip PA; Mohammad RM; Shields AF; Al Hallak MN; Azmi AS
    Mol Cancer Ther; 2023 Dec; 22(12):1422-1433. PubMed ID: 37703579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
    Bungaro M; Novello S; Passiglia F
    Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A saturation mutagenesis screen uncovers resistant and sensitizing secondary
    Feng S; Callow MG; Fortin JP; Khan Z; Bray D; Costa M; Shi Z; Wang W; Evangelista M
    Proc Natl Acad Sci U S A; 2022 May; 119(18):e2120512119. PubMed ID: 35471904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D-1553: A novel KRAS
    Shi Z; Weng J; Niu H; Yang H; Liu R; Weng Y; Zhu Q; Zhang Y; Tao L; Wang Z; Huh SJ; Jiang Y; Mei H; Dai X; Zhang L; Wang Y
    Cancer Sci; 2023 Jul; 114(7):2951-2960. PubMed ID: 37158138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
    Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
    Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.
    Sabari JK; Velcheti V; Shimizu K; Strickland MR; Heist RS; Singh M; Nayyar N; Giobbie-Hurder A; Digumarthy SR; Gainor JF; Rajan AP; Nieblas-Bedolla E; Burns AC; Hallin J; Olson P; Christensen JG; Kurz SC; Brastianos PK; Wakimoto H
    Clin Cancer Res; 2022 Aug; 28(15):3318-3328. PubMed ID: 35404402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy.
    Mukhopadhyay S; Huang HY; Lin Z; Ranieri M; Li S; Sahu S; Liu Y; Ban Y; Guidry K; Hu H; Lopez A; Sherman F; Tan YJ; Lee YT; Armstrong AP; Dolgalev I; Sahu P; Zhang T; Lu W; Gray NS; Christensen JG; Tang TT; Velcheti V; Khodadadi-Jamayran A; Wong KK; Neel BG
    Cancer Res; 2023 Dec; 83(24):4095-4111. PubMed ID: 37729426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors.
    Edwards AC; Stalnecker CA; Jean Morales A; Taylor KE; Klomp JE; Klomp JA; Waters AM; Sudhakar N; Hallin J; Tang TT; Olson P; Post L; Christensen JG; Cox AD; Der CJ
    Cancer Res; 2023 Dec; 83(24):4112-4129. PubMed ID: 37934103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
    Mainardi S; Mulero-Sánchez A; Prahallad A; Germano G; Bosma A; Krimpenfort P; Lieftink C; Steinberg JD; de Wit N; Gonçalves-Ribeiro S; Nadal E; Bardelli A; Villanueva A; Bernards R
    Nat Med; 2018 Jul; 24(7):961-967. PubMed ID: 29808006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.
    Misale S; Fatherree JP; Cortez E; Li C; Bilton S; Timonina D; Myers DT; Lee D; Gomez-Caraballo M; Greenberg M; Nangia V; Greninger P; Egan RK; McClanaghan J; Stein GT; Murchie E; Zarrinkar PP; Janes MR; Li LS; Liu Y; Hata AN; Benes CH
    Clin Cancer Res; 2019 Jan; 25(2):796-807. PubMed ID: 30327306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL-X
    Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification of Wild-type
    Bahcall M; Awad MM; Sholl LM; Wilson FH; Xu M; Wang S; Palakurthi S; Choi J; Ivanova EV; Leonardi GC; Ulrich BC; Paweletz CP; Kirschmeier PT; Watanabe M; Baba H; Nishino M; Nagy RJ; Lanman RB; Capelletti M; Chambers ES; Redig AJ; VanderLaan PA; Costa DB; Imamura Y; Jänne PA
    Clin Cancer Res; 2018 Dec; 24(23):5963-5976. PubMed ID: 30072474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 mediates clinical resistance to the KRAS
    Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
    Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.